DexCom, Inc. (dxcm)

DXCM — Company Overview

Investors tracking DXCM follow a Medical Devices name listed on NMS within Healthcare.

DXCM — Business Description

The business profile of DexCom, Inc. (DXCM) reflects its role in Medical Devices. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The c…

Official website: https://www.dexcom.com.

DXCM — Investment Thesis

DexCom, Inc. (DXCM) attracts investors weighing Medical Devices fundamentals against current market pricing.

• Revenue is expanding at roughly 13.1% year-over-year (public data).
• Trailing P/E of 35.38× implies elevated growth expectations at the current price.
• Forward P/E (28.08×) is below trailing P/E — earnings may be expected to improve.
• Equity market capitalization is approximately $33.11B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

DXCM — Financial Health

DXCM financial profile reflects operating efficiency and capital structure using available market fundamentals.

Profit margin of 20.1% indicates solid bottom-line conversion. Positive free cash flow of $1.02B supports balance-sheet flexibility.

DXCM — Growth Outlook

Growth outlook for DexCom, Inc. (DXCM) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 13.1% indicates strong top-line momentum.
• Earnings growth of 43.6% year-over-year supports improving profitability.
• Price is 5.2% below the 52-week high.

DXCM — Competitive Position

DexCom, Inc. (DXCM) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Medical Devices.
• Market capitalization of $33.11B places DXCM among large-cap peers.
• Gross margin near 62.5% may reflect pricing power or favorable mix.

DXCM — Summary

DexCom, Inc. (DXCM) is a large-cap Healthcare company focused on Medical Devices, listed on NMS. Last price $87.73 with market cap $33.11B. Trailing P/E 35.38×. Revenue grew 13.1% year-over-year per public data. Notable strengths include revenue growth of 13.1% year-over-year. Key watch items include elevated trailing p/e (35.38×) limits valuation margin of safety. Review free estimates and earnings pages for DXCM; upgrade for institutional ownership and live headlines.